So Far So Good on Our First Trade
Yesterday, at around 5 p.m. EST, the Anti-Infective Drugs Advisory Committee voted 12-0 to recommend that the FDA approve dalbavancin for ABSSSI. Congratulations if you bought the stock! This is exactly what we expected to happen, and now it's time to evaluate what our next step is going to be.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Ray Blanco’s FDA Trader
Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.